Cabaletta Bio, Inc

(NASDAQ:CABA)

Latest On Cabaletta Bio, Inc (CABA):

Date/Time Type Description Signal Details
2023-05-18 16:00 ESTNewsCabaletta Bio up 1%, prices $87M offeringN/A
2023-05-18 02:29 ESTNewsCabaletta Bio commences underwritten public offering of sharesN/A
2023-05-16 23:33 ESTNewsCabaletta Bio jumps 16% as FDA clears trial for myositis candidateN/A
2023-05-11 15:27 ESTNewsCabaletta Bio GAAP EPS of -$0.45 beats by $0.02N/A
2023-05-01 18:20 ESTNewsCabaletta's potential lupus drug CABA-201 gets FDA fast track tagN/A
2023-04-28 03:16 ESTNewsCabaletta Bio: Speculative Biotech With OpportunityN/A
2023-03-31 16:02 ESTNewsCabaletta CAR T cell therapy for lupus gets FDA nod to enter trialN/A
2023-03-31 16:02 ESTNews4 stocks to watch on Friday: Amazon, Kraft Heinz, and moreN/A
2023-03-16 13:19 ESTNewsCabaletta Bio GAAP EPS of -$0.52 misses by $0.08N/A
2023-01-27 17:59 ESTNewsCabaletta rises as Morgan Stanley upgrades citing new CAR-T assetN/A
2023-01-25 12:46 ESTNewsCabaletta: Adding To Position For 36% Return Potential After CABA-201 Rally (Technical Analysis)N/A
2022-12-08 20:30 ESTNewsCabaletta Bio dips on announcing $35M offeringN/A
2022-11-10 11:40 ESTNewsCabaletta Bio GAAP EPS of -$0.39 beats by $0.09N/A
2022-08-30 16:03 ESTNewsCabaletta downgraded at Morgan Stanley on upcoming data for lead assetN/A
2022-08-11 21:46 ESTNewsCabaletta Bio GAAP EPS of -$0.45 beats by $0.05N/A
2022-05-18 20:14 ESTNewsCabaletta Bio updates Phase 1 interim data for lead assetN/A
2022-05-12 11:04 ESTNewsCabaletta Bio GAAP EPS of -$0.45N/A
2022-03-18 09:46 ESTNewsCabaletta Bio GAAP EPS of -$0.49 beats by $0.11N/A
2021-12-14 08:41 ESTNewsCabaletta Bio tanks 34% on cell therapy data in early-stage study for pemphigus vulgarisN/A
2021-11-01 14:01 ESTNewsCabaletta Bio EPS beats by $0.05N/A
2021-11-01 14:01 ESTNewsCabaletta rises as skin diseases drug shown to be safe in early data of phase 1 trialN/A
2021-08-19 00:00 ESTNewsCabaletta Bio reports results from DesCAARTes trial in patients with pemphigus vulgarisN/A
2021-08-05 20:25 ESTNewsCabaletta Bio EPS beats by $0.03N/A
2021-03-18 15:25 ESTAnalyst RatingThe Analyst Target Price has increased from $20.33 to $22.25.Buy
2021-03-18 07:46 ESTFinancialsCompany financials have been released.Neutral
2021-03-17 17:01 ESTNewsCabaletta Bio EPS misses by $0.04N/A
2021-03-17 15:39 ESTEarnings EstimateAn EPS average of -$0.46 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-17 15:39 ESTEarnings EstimateAn EPS average of -$2.18 is estimated for the 2022 year.Sell
2021-01-20 12:58 ESTNewsCabaletta: DSG3-CAART's 1H 2021 Data Release Can Substantiate This Young BiotechN/A
2021-01-11 10:22 ESTAnalyst RatingThe Analyst Target Price has increased from $20 to $20.33.Buy
2021-01-09 03:37 ESTNewsChardan Capital initiates Cabaletta Bio with Buy ratingN/A
2020-12-10 06:47 ESTNewsDosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorderN/A
2020-12-04 06:26 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 00:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 15:51 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.67 to $20.Neutral
2020-11-17 07:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 23:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-12 07:15 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 09:52 ESTNewsCabaletta Bio EPS beats by $0.08N/A
2020-11-11 09:52 ESTNewsCabaletta Bio +5% on Q3 results, pipeline updateN/A
2020-11-11 06:54 ESTEarnings EstimateAn EPS average of -$0.44 is estimated for the quarter ending on March 31, 2021.Sell
2020-10-15 08:02 ESTNewsCabaletta Bio (CABA) Investor Presentation - SlideshowN/A
2020-10-14 11:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $22.5 to $21.67.Neutral
2020-10-08 21:07 ESTFinancialsCompany financials have been released.Neutral
2020-10-04 15:25 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 16:38 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 09:18 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 12:44 ESTFinancialsCompany financials have been released.Neutral
2020-08-10 03:29 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 23:40 ESTFinancialsCompany financials have been released.Neutral

About Cabaletta Bio, Inc (CABA):

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.

See Advanced Chart

General

  • Name Cabaletta Bio, Inc
  • Symbol CABA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 31
  • Fiscal Year EndDecember
  • IPO Date2019-10-25
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.cabalettabio.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 2.23
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.13
  • Next Year EPS Estimate -$2.45
  • Next Quarter EPS Estimate -$0.42
  • Return on Assets -17%
  • Return on Equity -27%
  • Earnings Per Share -$0.94
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 276.24 million
  • Analyst Target Price $22.25
View More

Share Statistics

  • Shares Outstanding 24.06 million
  • Shares Float 7.91 million
  • % Held by Insiders 523%
  • % Held by Institutions 67.4%
  • Shares Short 1.63 million
  • Shares Short Prior Month 1.61 million
  • Short Ratio 15.52
  • Short % of Float 8%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • 52 Week High $16.38
  • 52 Week Low $6.07
  • 50 Day Moving Average 11.96
  • 200 Day Moving Average 12.4
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Cabaletta Bio, Inc (CABA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Cabaletta Bio, Inc (CABA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-16$N/A-$0.40-$0.36-11.11%
2020-09-302020-11-10$N/A-$0.36-$0.4418.18%
2020-06-302020-08-06$N/A-$0.35-$0.3910.26%
2020-03-312020-05-12$N/A-$0.33-$0.23-43.48%
2019-12-312020-03-30$N/A-$0.33-$0.4729.79%
2019-09-302019-12-05$N/A-$1.21-$2.2646.46%

Cabaletta Bio, Inc (CABA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 5.78 million N/A N/A 4.62 million 3.03 million
Income Before Tax -9.31 million N/A N/A -7.49 million -5.4 million
Selling General Administrative 3.56 million N/A N/A 3.28 million 2.83 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -9.22 million N/A N/A -7.82 million -5.81 million
Operating Income -9.33 million N/A N/A -7.9 million -5.86 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A N/A
Net Income From Continuing Operations -9.31 million N/A N/A -7.49 million -5.4 million
Net Income Applicable to Common Shares -9.31 million -8.39 million -8.15 million N/A -5.4 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments 1.47 million N/A -226000 -273000 -40000
Change to Liabilities N/A -978000 N/A -306000 672000
Total Cash Flow from Investing Activities N/A -11.12 million N/A -273000 -40000
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 135000 N/A -44000 73.32 million -2.1 million
Change to Operating Activities N/A 315000 N/A -3.04 million 1.3 million
Change in Cash -3.42 million N/A -5.2 million 65.16 million -4.22 million
Total Cash from Operating Activities -5.02 million -7.64 million -4.93 million -7.88 million -2.08 million
Depreciation 90000 N/A 76000 51000 32000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A -147000 N/A 2.1 million -2.1 million
Change to Net Income N/A 1.1 million N/A 819000 569000
Capital Expenditures 162000 N/A 226000 273000 40000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 5.18 million 4.27 million N/A 3.26 million 3.15 million
Total Stockholder Equity 109.54 million 117.51 million N/A 131.71 million 138.32 million
Other Current Liabilities 38000 140000 N/A 101000 177000
Total Assets 114.72 million 121.77 million N/A 134.97 million 141.47 million
Common Stock N/A N/A N/A N/A N/A
Other Current Assets 1.85 million N/A N/A N/A N/A
Retained Earnings -66.3 million -56.99 million -48.6 million -40.44 million -32.96 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets 299000 N/A 238000 N/A 101000
Cash 101.43 million 108.68 million N/A 131 million 136.2 million
Total Current Liabilities 5.18 million 4.27 million N/A 3.26 million 3.15 million
Other Stockholder Equity 6000 N/A 11000 N/A N/A
Property, Plant & Equipment 890000 N/A 806000 N/A 815000
Total Current Assets 113.54 million 119.22 million N/A 134.12 million 140.55 million
Long Term Investments N/A 1.33 million N/A N/A N/A
Net Tangible Assets 109.54 million N/A 124.64 million N/A 138.32 million
Short Term Investments 7.23 million 8.06 million N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.24 million 953000 N/A 1.99 million 920000

Cabaletta Bio, Inc (CABA) Chart:

Cabaletta Bio, Inc (CABA) News:

Below you will find a list of latest news for Cabaletta Bio, Inc (CABA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Cabaletta Bio, Inc (CABA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-04-170.50CALL0 0420.32TRUE00
2026-04-1710CALL0 00TRUE00
2026-04-171.50CALL0 0156.56TRUE00
2026-04-1720.8CALL0 5156.53TRUE00
2026-04-172.50.35CALL12 25295.8TRUE-0.15-0.3
2026-04-1730.15CALL36 49297.92FALSE-0.05-0.25
2026-04-173.50.1CALL0 202183.27FALSE00
2026-04-1740.02CALL0 3047176.79FALSE00
2026-04-174.50.6CALL0 34307.38FALSE00
2026-04-1750.06CALL0 200200.67FALSE00
2026-04-175.50CALL0 0577.72FALSE00
2026-04-177.50CALL0 0644.79FALSE00
2026-04-170.50PUT0 00FALSE00
2026-04-1710PUT0 00FALSE00
2026-04-171.50PUT0 0891.27FALSE00
2026-04-1720PUT0 0609.21FALSE00
2026-04-172.50.23PUT1 305117.76FALSE0.110.92
2026-04-1730.35PUT0 35292.87TRUE00
2026-04-173.51.02PUT0 178.3TRUE00
2026-04-1740PUT0 0140.38TRUE00
2026-04-174.50PUT0 0127.45TRUE00
2026-04-1750PUT0 0187.61TRUE00
2026-04-175.50PUT0 0206.5TRUE00
2026-04-177.50PUT0 00TRUE00
2026-05-150.50CALL0 00TRUE00
2026-05-1512.2CALL0 880TRUE00
2026-05-151.51.92CALL0 226102.42TRUE00
2026-05-1521.27CALL0 145284.11TRUE00
2026-05-152.50.35CALL18 1507363.97TRUE-0.18-0.34
2026-05-1530.55CALL0 596128.87FALSE00
2026-05-153.50.28CALL82 617131.77FALSE0.080.4
2026-05-1540.1CALL0 438225.34FALSE00
2026-05-154.50.4CALL0 31182.01FALSE00
2026-05-1550.05CALL5 3587113.4FALSE00
2026-05-155.50CALL0 0392.03FALSE00
2026-05-157.50.04CALL0 1055188.08FALSE00
2026-05-150.50PUT0 0404.61FALSE00
2026-05-1510PUT0 00FALSE00
2026-05-151.50PUT0 0607.42FALSE00
2026-05-1520.5PUT0 1415.29FALSE00
2026-05-152.50.35PUT0 447126.22FALSE00
2026-05-1530.69PUT0 387.41TRUE00
2026-05-153.50.87PUT0 100133.25TRUE00
2026-05-1541.22PUT0 498.04TRUE00
2026-05-154.51.5PUT0 2115.88TRUE00
2026-05-1552.1PUT0 20131.07TRUE00
2026-05-155.50PUT0 0144.34TRUE00
2026-05-157.54.15PUT0 330TRUE00
2026-08-210.52.6CALL0 20TRUE00
2026-08-2110CALL0 089.19TRUE00
2026-08-211.51.65CALL0 1378.3TRUE00
2026-08-2122CALL0 58120.88TRUE00
2026-08-212.50.8CALL0 1390479.25TRUE00
2026-08-2130.6CALL0 3640134.18FALSE00
2026-08-213.50.8CALL0 113123.69FALSE00
2026-08-2140.75CALL0 13198.67FALSE00
2026-08-214.50CALL0 0210.74FALSE00
2026-08-2150.45CALL0 64221FALSE00
2026-08-215.50.5CALL0 9159.7FALSE00
2026-08-217.50CALL0 0256.85FALSE00
2026-08-210.50PUT0 00FALSE00
2026-08-2110PUT0 00FALSE00
2026-08-211.50PUT0 0361.47FALSE00
2026-08-2120PUT0 0247.34FALSE00
2026-08-212.50.5PUT0 11116.39FALSE00
2026-08-2130.8PUT0 0105.47TRUE00
2026-08-213.50PUT0 0103.88TRUE00
2026-08-2140PUT0 0112.29TRUE00
2026-08-214.50PUT0 0117.55TRUE00
2026-08-2152.35PUT0 19120.47TRUE00
2026-08-215.50PUT0 0112.5TRUE00
2026-08-217.50PUT0 0118.11TRUE00
2026-09-180.53CALL0 17197.23TRUE00
2026-09-1812.6CALL0 7114.51TRUE00
2026-09-181.51.5CALL2 75140.1TRUE1.50
2026-09-1821.65CALL0 767110.45TRUE00
2026-09-182.51CALL1 6276128.71TRUE-0.1-0.09
2026-09-1831.26CALL0 3528151.71FALSE00
2026-09-183.50.85CALL0 35596.41FALSE00
2026-09-1840.57CALL0 35127.23FALSE00
2026-09-184.50.8CALL0 41193.2FALSE00
2026-09-1850.5CALL0 330181.96FALSE00
2026-09-185.50.55CALL0 71210.8FALSE00
2026-09-187.50.4CALL0 1005153.39FALSE00
2026-09-180.50PUT0 00FALSE00
2026-09-1810PUT0 00FALSE00
2026-09-181.50.2PUT0 1332.83FALSE00
2026-09-1820PUT0 0147.88FALSE00
2026-09-182.50.77PUT0 40122.62FALSE00
2026-09-1831.25PUT0 38125.27TRUE00
2026-09-183.51.65PUT0 7123.14TRUE00
2026-09-1841.87PUT0 35117.61TRUE00
2026-09-184.52.2PUT0 1115.97TRUE00
2026-09-1852.7PUT0 8111.76TRUE00
2026-09-185.50PUT0 0120.45TRUE00
2026-09-187.50PUT0 0130.7TRUE00
2026-11-200.50CALL0 0201.97TRUE00
2026-11-2010CALL0 0182.79TRUE00
2026-11-201.50CALL0 0161.64TRUE00
2026-11-2020CALL0 0158.88TRUE00
2026-11-202.50CALL0 0159.17TRUE00
2026-11-2030CALL0 0155.91FALSE00
2026-11-203.50CALL0 0150.59FALSE00
2026-11-2040CALL0 0149.86FALSE00
2026-11-204.50CALL0 0141.77FALSE00
2026-11-2050.8CALL0 20132.67FALSE00
2026-11-205.50CALL0 0134.03FALSE00
2026-11-200.50PUT0 00FALSE00
2026-11-2010PUT0 00FALSE00
2026-11-201.50PUT0 0288.04FALSE00
2026-11-2020.55PUT0 1136.26FALSE00
2026-11-202.51PUT0 6162.73FALSE00
2026-11-2030PUT0 0146.99TRUE00
2026-11-203.50PUT0 0155.85TRUE00
2026-11-2040PUT0 0131.99TRUE00
2026-11-204.50PUT0 0148.5TRUE00
2026-11-2050PUT0 0157.58TRUE00
2026-11-205.50PUT0 0142.23TRUE00
2027-01-150.53.22CALL0 1238.96TRUE00
2027-01-1512.1CALL0 12149.54TRUE00
2027-01-151.52.4CALL0 1154.71TRUE00
2027-01-1522CALL0 56150.34TRUE00
2027-01-152.51.8CALL0 367170.98TRUE00
2027-01-1531.31CALL0 410185.77FALSE00
2027-01-153.51.25CALL1 40158.57FALSE1.250
2027-01-1541.35CALL0 23156.88FALSE00
2027-01-154.51.13CALL0 20143.25FALSE00
2027-01-1550.82CALL0 880124.31FALSE00
2027-01-155.50.95CALL0 17125.57FALSE00
2027-01-150.50PUT0 00FALSE00
2027-01-1510PUT0 00FALSE00
2027-01-151.50.65PUT0 12187.68FALSE00
2027-01-1520.75PUT0 56187.47FALSE00
2027-01-152.51PUT0 26147.69FALSE00
2027-01-1531.3PUT0 1158.27TRUE00
2027-01-153.50PUT0 0153.39TRUE00
2027-01-1542PUT0 50147.47TRUE00
2027-01-154.52.7PUT0 2146.09TRUE00
2027-01-1552.6PUT0 5122.65TRUE00
2027-01-155.53PUT0 50119.37TRUE00
2028-01-210.52.6CALL6 9269.71TRUE-0.1-0.04
2028-01-2112.5CALL0 2170.52TRUE00
2028-01-211.51.86CALL0 44180.62TRUE00
2028-01-2122.24CALL4 312192.11TRUE-0.56-0.2
2028-01-212.52CALL2 240163.49TRUE20
2028-01-2131.9CALL5 96159.14FALSE1.90
2028-01-213.52CALL0 10172.1FALSE00
2028-01-2141.75CALL3 45155.31FALSE1.750
2028-01-214.51.95CALL0 10160.34FALSE00
2028-01-2152.35CALL0 102169.81FALSE00
2028-01-215.51.52CALL1 109147.15FALSE1.520
2028-01-210.50PUT0 00FALSE00
2028-01-2110PUT0 0177.37FALSE00
2028-01-211.50PUT0 0191.4FALSE00
2028-01-2121.1PUT0 5188.8FALSE00
2028-01-212.51.5PUT0 40163.53FALSE00
2028-01-2132PUT0 705174.46TRUE00
2028-01-213.52.3PUT0 4154.21TRUE00
2028-01-2140PUT0 0167.44TRUE00
2028-01-214.50PUT0 0163.74TRUE00
2028-01-2153.5PUT0 45169.78TRUE00
2028-01-215.53.9PUT0 2165.44TRUE00

Latest CABA Trades:

Date Shares Price
Jun 13, 2022 7:37 PM EST1$1.08
Jun 13, 2022 7:37 PM EST6$1.08
Jun 13, 2022 7:51 PM EST7$1.06
Jun 13, 2022 7:57 PM EST7$1.06
Jun 13, 2022 7:58 PM EST7$1.055

Cabaletta Bio, Inc (CABA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520159049/0001193125-20-159049-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025941/0000899243-19-025941-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025942/0000899243-19-025942-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025943/0000899243-19-025943-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025946/0000899243-19-025946-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025947/0000899243-19-025947-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026016/0000899243-19-026016-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026017/0000899243-19-026017-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026018/0000899243-19-026018-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026020/0000899243-19-026020-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026345/0000899243-19-026345-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026346/0000899243-19-026346-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320004509/0000899243-20-004509-index.htm
2020-02-135Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320004511/0000899243-20-004511-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006864/0000899243-20-006864-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006865/0000899243-20-006865-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006867/0000899243-20-006867-index.htm
2020-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320025326/0000899243-20-025326-index.htm
2020-07-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000090266420002724/0000902664-20-002724-index.htm
2019-11-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000092963819000988/0000929638-19-000988-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000092963820000331/0000929638-20-000331-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919056233/0001104659-19-056233-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919057348/0001104659-19-057348-index.htm
2019-10-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919058504/0001104659-19-058504-index.htm
2019-11-12SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1759138/000110465919061822/0001104659-19-061822-index.htm
2019-10-24S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1759138/000119312519273939/0001193125-19-273939-index.htm
2019-10-25424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1759138/000119312519274807/0001193125-19-274807-index.htm
2019-10-29S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1759138/000119312519277804/0001193125-19-277804-index.htm
2019-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312519278927/0001193125-19-278927-index.htm
2019-11-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119312519287367/0001193125-19-287367-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520005110/0001193125-20-005110-index.htm
2020-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520017724/0001193125-20-017724-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520038349/0001193125-20-038349-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520042689/0001193125-20-042689-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520090013/0001193125-20-090013-index.htm
2020-03-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520091086/0001193125-20-091086-index.htm
2020-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520115863/0001193125-20-115863-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520134391/0001193125-20-134391-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520139782/0001193125-20-139782-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520153792/0001193125-20-153792-index.htm
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520159049/0001193125-20-159049-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520211336/0001193125-20-211336-index.htm
2019-10-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119380519001374/0001193805-19-001374-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000119380519001376/0001193805-19-001376-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119380520000185/0001193805-20-000185-index.htm
2019-12-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459019045375/0001564590-19-045375-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1759138/000156459020013929/0001564590-20-013929-index.htm
2020-05-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459020024508/0001564590-20-024508-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459020037278/0001564590-20-037278-index.htm
2019-10-24EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1759138/999999999519002384/9999999995-19-002384-index.htm

Cabaletta Bio, Inc (CABA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cabaletta Bio, Inc (CABA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 523%
Institutional Ownership: 6740%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-10-295AM Ventures V, L.P.10% Share HolderBuy454,545.0011.004,999,995.00454,545.00https://www.sec.gov/Archives/edgar/data/1759138/000110465919058504/0001104659-19-058504-index.htm
2019-10-29James E Flynn10% Share HolderBuy700,000.0011.007,700,000.00700,000.00https://www.sec.gov/Archives/edgar/data/1759138/000119380519001376/0001193805-19-001376-index.htm